GlassScriptPhysician profile
Fanwei Meng
NPI 1780650937
$4,314.33
in general payments reported to CMS, 2019-2025
33 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.22 · 2020: $49.14 · 2022: $559 · 2023: $800 · 2024: $1,475 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,657 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,657.20 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $570.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $517.75 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $473.16 | 2022-2025 | |
| Novo Nordisk INC | $381.82 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $340.17 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $311.67 | 2019-2025 | |
| Amgen INC. | $228.71 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $198.87 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $127.95 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.97 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $115.65 | 2022-2023 | |
| Exact Sciences Corporation | $110.50 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $97.84 | 2022-2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $84.50 | 2023-2025 | Gemtesa |
| Shield Therapeutics INC | $71.90 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $62.92 | 2022-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Otsuka America Pharmaceutical, INC. | $56.84 | 2024-2025 | Rexulti |
| Currax Pharmaceuticals LLC | $53.49 | 2022-2023 | Nexletol |
| Dynavax Technologies Corporation | $48.32 | 2023-2024 | Heplisav-B |
| Daiichi Sankyo INC. | $45.52 | 2022-2024 | Injectafer |
| Astellas Pharma US INC | $40.58 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $32.03 | 2022 | |
| Cvrx, INC. | $31.72 | 2024-2025 | Barostim Neo System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.93 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $24.78 | 2024 | Trelegy Ellipta, Arexvy |
| Inari Medical, INC. | $21.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $20.88 | 2025 | Capvaxive, Gardasil 9 |
| Stryker Corporation | $19.04 | 2025 | Clottriever Bold Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2023 | |
| Corcept Therapeutics | $16.75 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $16.45 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fanwei Meng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.